Does TRICARE Cover Jatenzo? Coverage Rules, Prior Auth, and Appeals

What Is Jatenzo and Why Does Formulary Placement Matter?

Jatenzo is the first FDA-approved oral testosterone therapy designed to bypass hepatic first-pass metabolism by absorbing through intestinal lymphatics. The FDA granted approval in March 2019 based on the key Phase III trial by Swerdloff et al., which enrolled 166 hypogonadal men and demonstrated that 87% achieved mean total testosterone within the eugonadal range (300 to 1 to 000 ng/dL) over 105 days of twice-daily dosing with food [1]. Doses are titrated from 158 mg to 237 mg twice daily depending on serum testosterone response at weeks 4 and 8 [2].

Because Jatenzo is a brand-only product with no generic equivalent, TRICARE places it in a non-preferred tier. Injectable testosterone cypionate and testosterone enanthate are available as low-cost generics and sit on the preferred formulary. That gap in cost drives the prior authorization process: TRICARE contractors want evidence that a preferred agent was tried or is genuinely contraindicated before funding a $900-per-month oral option.

For servicemembers and their dependents, the stakes of getting coverage right are high. Untreated hypogonadism is associated with reduced bone mineral density, loss of lean mass, impaired erythropoiesis, and metabolic dysfunction [3]. The Endocrine Society's 2018 clinical practice guideline recommends testosterone therapy for men with classic hypogonadism who have consistent symptoms and unequivocally low serum testosterone [4].

How TRICARE's Formulary Is Structured for Testosterone Products

TRICARE uses a three-tier formulary managed through the TRICARE Pharmacy Program, administered by Express Scripts (now Esi/Envolve under the TRICARE Pharmacy Benefits Program contract). Tier 1 covers generic drugs at the lowest cost share. Tier 2 covers formulary brand drugs. Tier 3 covers non-formulary brands, and Jatenzo sits here in most TRICARE regions [5].

At a Tier 3 non-formulary placement, active-duty servicemembers pay a higher cost share at retail pharmacies and cannot fill Jatenzo at military treatment facility pharmacies without a formulary exception. TRICARE beneficiaries using TRICARE Prime or TRICARE Select face different cost-share structures, but the prior-authorization requirement applies to both plans.

TRICARE's National Pharmacy Program maintains a searchable formulary at the TRICARE website; however, formulary status can change between fiscal years. Prescribers should verify current tier placement before submitting a prior authorization to avoid delays caused by using outdated criteria forms.

For context on how testosterone deficiency is diagnosed and managed before reaching the formulary question, the American Urological Association (AUA) 2018 testosterone deficiency guideline states: "Clinicians should use a total testosterone level below 300 ng/dL as a reasonable cut-off in support of the diagnosis of low testosterone" [6].

Prior Authorization Criteria for Jatenzo Under TRICARE

Getting prior authorization approved requires satisfying several specific clinical criteria that TRICARE contractors review. The core requirements seen across TRICARE regional contractors are:

Diagnosis confirmation. Two separate morning fasting serum total testosterone measurements below 300 ng/dL, drawn on different days, using a reliable assay. The Swerdloff Phase III study used LC-MS/MS methodology, which the Endocrine Society also recommends for diagnostic accuracy when immunoassay results are borderline [4]. If total testosterone is near the lower limit of normal, free testosterone by equilibrium dialysis may be required.

Symptom documentation. The prescriber must document clinical signs consistent with hypogonadism. These typically include at least two of: decreased libido, erectile dysfunction, fatigue, depressed mood, decreased lean mass, or reduced bone density. The Endocrine Society guideline explicitly notes that testosterone therapy should not be started based on low levels alone without symptoms [4].

Etiology. TRICARE requires an identified cause, whether primary (testicular failure, confirmed by elevated LH and FSH) or secondary (hypothalamic or pituitary dysfunction, confirmed by low or inappropriately normal LH and FSH). Idiopathic late-onset hypogonadism without a confirmed structural or genetic etiology may receive more scrutiny.

Step therapy. At least one preferred testosterone formulation must have been tried at an adequate dose for at least 90 days, or there must be a documented contraindication or intolerance. Testosterone cypionate 200 mg IM every two weeks is the most common step-therapy requirement. Topical gel 1% (generic AndroGel) is a common second-step agent. Jatenzo's oral route may be the clinical rationale when injections are contraindicated due to bleeding disorders, needle phobia with documented psychiatric history, or when topicals create exposure risk to partners or children.

Prescriber type. In many TRICARE regions, the prescribing provider should be a urologist, endocrinologist, or internist with documented testosterone management experience. Primary care prescriptions for Jatenzo may receive more scrutiny.

A study published in the Journal of Clinical Endocrinology and Metabolism confirmed that oral testosterone undecanoate significantly raised serum testosterone in hypogonadal men compared with placebo, with 87% of participants achieving levels within the normal range [1]. That evidence base supports the clinical necessity argument used in prior authorization requests.

The HealthRX clinical team compiled the following three-part documentation framework based on review of TRICARE prior authorization submission patterns across 2023 and 2024. Prescribers who include all three elements at initial submission have a substantially higher first-pass approval rate than those who submit incomplete packages.

Element 1: Lab packet. Two testosterone panels (total testosterone, LH, FSH, SHBG, prolactin, and CBC) drawn on separate mornings, with collection times between 7 a.m. and 10 a.m. noted on the lab slip.

Element 2: Clinical narrative. A signed letter from the prescriber summarizing symptom onset, duration, functional impact, response to prior testosterone therapy (including dose, duration, and reason for discontinuation), and why Jatenzo's oral lymphatic absorption pathway is medically necessary for this specific patient.

Element 3: Step-therapy documentation. Pharmacy dispensing records or a prior-authorization approval letter for the previous testosterone agent, plus a dated clinical note documenting the reason for discontinuation (e.g., injection site reactions, hematocrit rise above 54%, or transfer risk to partner).

Step Therapy Requirements: Which Testosterone Products Come First?

TRICARE's step therapy for Jatenzo generally proceeds in this order, though specific regional contractors may vary.

First, injectable testosterone. Testosterone cypionate and testosterone enanthate are both available as generics, typically costing under $40 per month at a military treatment facility pharmacy. The FDA label for testosterone cypionate injection notes typical dosing of 50 to 400 mg IM every two to four weeks [7]. Failure at this step means either a documented adverse event (excessive erythrocytosis with hematocrit above 54%, significant injection-site complications) or a contraindication.

Second, topical testosterone. Generic testosterone gel 1% delivers steady-state levels with less peak-and-trough variability than biweekly injections. The main clinical reasons it fails are: documented transfer to a partner or child despite barrier precautions, skin conditions preventing application, or patient non-adherence with documented washout failure. A randomized trial published in the New England Journal of Medicine showed that testosterone gel normalized serum testosterone in 80% of hypogonadal men at 90 days, establishing it as an effective first-line option [8].

Third, other branded formulations. Testosterone nasal gel (Natesto) and testosterone pellets (Testopel) may appear as intermediate steps in some TRICARE contractor criteria before Jatenzo is approved.

Only after documented failure of or contraindication to agents in the first two categories will TRICARE routinely approve Jatenzo as the medically necessary alternative.

What to Do When TRICARE Denies Jatenzo

A denial letter from the TRICARE pharmacy contractor is not the end of the road. The Defense Health Agency's appeals process has multiple levels, and many initial denials are overturned when complete clinical documentation is submitted at the first appeal level.

Level 1: Contractor-level appeal. Submit a written appeal to the regional TRICARE contractor (Humana Military for the East region, Health Net Federal Services for the West region) within 90 days of the denial date. Include the full documentation framework described above, plus any new clinical evidence. The contractor must respond within 30 days for non-urgent requests, or 72 hours for expedited urgent requests.

Level 2: Independent review. If the contractor upholds the denial, beneficiaries may request an independent review by the Defense Health Agency within 60 days. This review is conducted by clinicians who are not affiliated with the contractor.

Level 3: Formal grievance. A formal written grievance to the Defense Health Agency is the third level. At this stage, having a patient advocate or attorney familiar with TRICARE appeals regulations (32 CFR Part 199) is advisable.

During the appeals process, the prescriber should submit a letter of medical necessity that directly references the Endocrine Society guideline language. The guideline states: "We recommend treatment of androgen-deficient men with exogenous androgen therapy to induce and maintain secondary sexual characteristics and correct symptoms of androgen deficiency" [4]. Aligning the appeal language with published clinical practice guidelines strengthens the medical necessity argument.

The FDA's prescribing information for Jatenzo notes that the drug carries a boxed warning for blood pressure increases; mean increases of 3 to 5 mmHg systolic were observed in clinical trials [2]. Prescribers should document baseline and follow-up blood pressure in the chart, both because it is clinically required and because it demonstrates the kind of thorough monitoring TRICARE reviewers expect to see in appeals packages.

Jatenzo Blood Pressure Warning and Its Effect on Coverage Decisions

The boxed warning for blood pressure is unique to oral testosterone undecanoate and does not appear on injectable testosterone labels. In the key trial, systolic blood pressure increased a mean of 4.9 mmHg from baseline in men taking Jatenzo [2]. The FDA requires blood pressure monitoring at each clinical visit and recommends that Jatenzo not be used in men with uncontrolled hypertension [2].

TRICARE medical reviewers occasionally use the blood pressure boxed warning as additional grounds for denial, particularly in beneficiaries with pre-existing cardiovascular risk factors. Prescribers can preempt this by including a cardiovascular risk assessment in the prior authorization package, documenting that the patient's blood pressure is controlled (below 130/80 mmHg per ACC/AHA 2017 guidelines [9]) and that the prescriber has a monitoring plan in place.

Research published in the Journal of Clinical Endocrinology and Metabolism found that despite the modest blood pressure increase, no serious cardiovascular events were attributable to Jatenzo during the 105-day Phase III study period [1]. Citing this finding in the appeal reinforces that the benefit-risk profile was acceptable in the clinical trial population.

Cost Without Coverage and Manufacturer Savings Programs

Without TRICARE coverage, Jatenzo carries a list price of approximately $900 per month. The manufacturer, Clarus Therapeutics (now Halozyme after acquisition), has offered a savings card program for commercially insured patients. However, federal law (42 U.S.C. Section 1320a-7b) prohibits the use of manufacturer copay cards for any federal health program, including TRICARE, Medicare, and Medicaid [10].

TRICARE beneficiaries cannot legally use the Jatenzo savings card to offset their cost share. This is a firm prohibition, not a policy recommendation. Providers who instruct TRICARE patients to use manufacturer cards expose themselves and the patient to federal anti-kickback risk.

Alternatives for cost reduction include:

Requesting a formulary exception through the TRICARE Pharmacy Benefits Program if there is documented medical necessity. An approved exception can move Jatenzo to a lower cost-share tier for that individual beneficiary.

Discussing whether a compounded testosterone preparation might meet clinical needs, though compounded testosterone does not carry FDA approval and TRICARE coverage for compounded drugs is extremely limited [11].

Pursuing the appeals pathway to secure full prior authorization rather than paying out of pocket.

Monitoring Requirements That Support Ongoing Authorization Renewals

Prior authorizations for Jatenzo are typically granted for 12 months and require renewal. Demonstrating treatment response and ongoing safety monitoring is the key to smooth renewals.

The Endocrine Society recommends checking serum testosterone (drawn three to five hours after morning dose with Jatenzo specifically, due to its lymphatic absorption kinetics) at three to six months after initiation, then annually [4]. The target range is 400 to 700 ng/dL at the expected peak for oral formulations.

Hematocrit must be checked at three to six months and annually. The FDA label for Jatenzo recommends withholding therapy if hematocrit exceeds 54% [2]. PSA should be measured at three to six months and then annually in men over 40, consistent with the Endocrine Society guideline [4].

Bone mineral density by DEXA scan is appropriate at baseline and every one to two years in men with confirmed osteoporosis or fragility fracture, given that hypogonadism is a recognized cause of secondary osteoporosis [3]. Including DEXA results in the renewal package demonstrates comprehensive management and supports continued medical necessity.

Blood pressure must be documented at each visit, per the boxed warning. A log of stable blood pressure readings in a patient who initially had borderline elevation is actually helpful for renewal, demonstrating that the prescriber is managing the known risk appropriately.

For TRICARE authorization renewals, submit the renewal request 60 to 90 days before the current authorization expires to avoid a coverage gap. Include the most recent lab results, a brief clinical summary of treatment response, and updated blood pressure readings.

How Jatenzo Compares to Preferred Testosterone Formulations

Understanding why TRICARE places Jatenzo below generic testosterone on the formulary helps prescribers write stronger step-therapy failure documentation.

Testosterone cypionate injection achieves mean trough levels that vary substantially between doses, producing peak-to-trough fluctuations that some patients experience as mood swings or energy variability. A study in the Journal of Clinical Endocrinology and Metabolism showed that mean total testosterone peaked above 1 to 200 ng/dL at day two post-injection and fell below 300 ng/dL by day 14 with the standard 200 mg biweekly schedule [12]. For a patient who reliably documents symptoms of hypogonadism returning in the week before the next injection, that pharmacokinetic data is clinically meaningful documentation of step-therapy failure.

Testosterone gel 1% delivers more stable levels but requires daily application and carries a risk of transference to household contacts. The FDA added a black box warning for secondary exposure in children in 2009, based on reports of premature puberty in boys and virilization in girls who had contact with gel-treated men [13]. A servicemember with young children at home has a documented safety rationale for preferring Jatenzo's oral route over topical therapy.

Jatenzo, dosed twice daily with meals, achieves a more physiologic diurnal pattern than biweekly injections, though it does not replicate the morning peak seen in healthy men. The Swerdloff trial confirmed that mean total testosterone after Jatenzo dosing averaged 498 ng/dL at steady state, well within the normal range [1].

TRICARE and Jatenzo for Indications Beyond Hypogonadism

TRICARE will not cover Jatenzo for off-label indications. The FDA approved Jatenzo specifically for adult men with primary or hypogonadotropic hypogonadism [2]. Use for age-related testosterone decline without a confirmed diagnosis, for body composition goals, or for athletic performance is off-label and will be denied by TRICARE without exception.

Specifically, Jatenzo is not approved or covered for weight loss. Testosterone therapy may produce modest reductions in fat mass as a secondary effect in hypogonadal men, but the indication must be confirmed hypogonadism, not obesity alone. A 2013 meta-analysis in the European Journal of Endocrinology found that testosterone therapy in hypogonadal men reduced fat mass by a mean of 1.6 kg compared with placebo, but no testosterone preparation carries an FDA weight-loss indication [14]. Any prior authorization or appeal framed around weight loss as the primary indication will be denied.